Denali Therapeutics Inc. (DNLI) is a Biotechnology company in the Healthcare sector, currently trading at $20.16. It has a SharesGrow Score of 61/100, indicating a above average investment profile with 2 out of 7 criteria passed.
Analyst consensus target is DNLI = $34 (+70.6% upside).
Valuation: DNLI trades at a trailing Price-to-Earnings (P/E) of -6.7 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 1.78.
Net income is $513M (loss), growing at -52.3%/yr. Net profit margin is 0% (thin). Gross margin is 94.9% (+1.4 pp trend).
Balance sheet: total debt is $42M against $1.0B equity (Debt-to-Equity (D/E) ratio 0.04, conservative). Current ratio is 9.16 (strong liquidity). Debt-to-assets is 3.7%. Total assets: $1.1B.
Analyst outlook: 17 / 17 analysts rate DNLI as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 58/100 (Partial), Growth 58/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 58/100 (Partial), Future 100/100 (Pass), Income ?/100 (Fail).
